Also have to take total revenues in the context of this statement re respitory products...
"Revenues from the Company’s respiratory product line (Breath-A-Tech and Funhaler) were down slightly
reflecting historical seasonal trends and the Company’s decision to cease sales and marketing efforts for the respiratory line outside of Australia."
So there growth will come from recell as they are now only marketing in Austrlia for other products
avita medical reports strong half year financi, page-19
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.84 |
Change
-0.120(3.03%) |
Mkt cap ! $268.3M | |||
| Open | High | Low | Value | Volume |
| $3.94 | $3.94 | $3.76 | $511.0K | 134.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $3.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.84 | 11883 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |